Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Drug summary box.
| Drug name | Tivozanib |
| Phase | III |
| Indication | Advanced RCC (pending) |
| Pharmacology Description/Mechanism of Action | Multi-targeted receptor tyrosine kinase inhibitor with high specificity for VEGFR-1, -2, and -3 |
| Route of Administration | Oral |
| Chemical Formula | C22H19ClN4O5 |
| Pivotal Trial | Phase III TIVO-1 study in mRCC comparing sorafenib and tivozanib monotherapy in patients with 0-1 prior lines of therapy (excluding VEGF- or mTOR-directed therapies) |
